A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

Crit Rev Immunol. 2001;21(1-3):249-61.

Abstract

Prostate-specific membrane antigen (PSMA) is a potential target in prostate cancer patients because it is very highly expressed and because it has been reported to be upregulated by androgen deprivation. This review discusses the historical background, biochemical characteristics, gene regulation, potential for targeting, tissue localization, and a novel T-body strategy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Alternative Splicing
  • Animals
  • Antibodies, Monoclonal
  • Antigens, Surface*
  • Binding Sites
  • Cancer Vaccines / immunology
  • Carboxypeptidases / analysis*
  • Carboxypeptidases / genetics
  • Cloning, Molecular
  • Genetic Therapy
  • Glutamate Carboxypeptidase II
  • Humans
  • Male
  • Mice
  • Prostate / diagnostic imaging
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / therapy*
  • Radionuclide Imaging

Substances

  • Antibodies, Monoclonal
  • Antigens, Surface
  • Cancer Vaccines
  • Carboxypeptidases
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II